中国执业药师
中國執業藥師
중국집업약사
CHINA LICENSED PHARMACIST
2014年
6期
35-38
,共4页
他克莫司%新发糖尿病%器官移植%发病机制%进展
他剋莫司%新髮糖尿病%器官移植%髮病機製%進展
타극막사%신발당뇨병%기관이식%발병궤제%진전
Tacrolimus%New-onset Diabetes Mellitus (NODM)%Organ Transplantation%Nosogenesis%Progress
器官移植术后新发糖尿病是实体器官移植后的主要并发症之一,免疫抑制常被认为是导致器官移植术后新发糖尿病的主要因素,包括糖皮质激素、钙调磷酸酶抑制剂等。其中,钙调磷酸酶抑制剂对血糖的影响最大。他克莫司是从链霉菌属中分离出的发酵产物,是一种强效免疫抑制性大环内酯类抗生素,现广泛用于实体器官移植的免疫抑制剂。他克莫司对细胞免疫有选择性抑制作用,主要通过抑制白细胞介素-2的释放,全面抑制 T 淋巴细胞的作用。通过查阅文献,从三方面综述了他克莫司引起高血糖的机制,包括影响β细胞存活和复制、影响胰岛素分泌、影响外周组织的胰岛素利用。
器官移植術後新髮糖尿病是實體器官移植後的主要併髮癥之一,免疫抑製常被認為是導緻器官移植術後新髮糖尿病的主要因素,包括糖皮質激素、鈣調燐痠酶抑製劑等。其中,鈣調燐痠酶抑製劑對血糖的影響最大。他剋莫司是從鏈黴菌屬中分離齣的髮酵產物,是一種彊效免疫抑製性大環內酯類抗生素,現廣汎用于實體器官移植的免疫抑製劑。他剋莫司對細胞免疫有選擇性抑製作用,主要通過抑製白細胞介素-2的釋放,全麵抑製 T 淋巴細胞的作用。通過查閱文獻,從三方麵綜述瞭他剋莫司引起高血糖的機製,包括影響β細胞存活和複製、影響胰島素分泌、影響外週組織的胰島素利用。
기관이식술후신발당뇨병시실체기관이식후적주요병발증지일,면역억제상피인위시도치기관이식술후신발당뇨병적주요인소,포괄당피질격소、개조린산매억제제등。기중,개조린산매억제제대혈당적영향최대。타극막사시종련매균속중분리출적발효산물,시일충강효면역억제성대배내지류항생소,현엄범용우실체기관이식적면역억제제。타극막사대세포면역유선택성억제작용,주요통과억제백세포개소-2적석방,전면억제 T 림파세포적작용。통과사열문헌,종삼방면종술료타극막사인기고혈당적궤제,포괄영향β세포존활화복제、영향이도소분비、영향외주조직적이도소이용。
New-onset diabetes mellitus (NODM) after organ transplantation is one of the major complications after solid organ transplantation. Immunosuppression is considered as the main factor leading to NODM after organ transplantation, the immunosuppressive agents include glucocorticoids and calcineurin inhibitors, etc. and calcineurin inhibitors have a big effect on blood sugar. Tacrolimus is the fermented products isolated from Streptomyces, it is a macrolide antibiotic with potent immunosuppression and is now widely used as an immune inhibitor in organ transplants. Tacrolimus has a selective inhibitory action on cellular immunity, primarily by inhibiting the release of leukotriene -2 to inhibit the role of T lymphocytes. Based on the research of foreign literatures, this paper respectively discussed from three aspects of mechanism of hyperglycemia induced by tacrolimus, including the effects on β-cell survival and replication, insulin secretion and the influence of peripheral tissue insulin action.